Skip to main content

Editas Medicine, Inc. (EDIT)

NASDAQ: EDIT · IEX Real-Time Price · USD
61.31 -0.76 (-1.22%)
Sep 24, 2021 11:19 AM EDT - Market open
Market Cap4.03B
Revenue (ttm)81.14M
Net Income (ttm)-166.66M
Shares Out67.88M
EPS (ttm)-2.58
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close62.07
Day's Range59.75 - 61.47
52-Week Range27.01 - 99.95
Price Target53.92 (-12.1%)
Est. Earnings DateNov 4, 2021

About EDIT

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is...

IPO DateFeb 3, 2016
CEOCynthia Collins
Stock ExchangeNASDAQ
Ticker SymbolEDIT
Full Company Profile

Financial Performance

In 2020, EDIT's revenue was $90.73 million, an increase of 341.93% compared to the previous year's $20.53 million. Losses were -$115.98 million, -13.29% less than in 2019.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price forecast is 53.92, which is a decrease of -12.05% from the latest price.

Price Target
(-12.05% downside)
Analyst Consensus: Buy


Why Cathie Wood Is Buying 2 Gene-Editing Stocks but Selling Another

Wood is following an important strategy with gene-editing stocks.

Other symbols:BEAMCRSPVRTX
1 day ago - The Motley Fool

Buying This Beaten-Down ETF Could Double Your Money Over the Next 5 Years

It could perhaps deliver a much bigger gain than 100%.

1 day ago - The Motley Fool

7 Gene Editing Stocks Promising to Change our DNA

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared fi...

1 week ago - InvestorPlace

Final Trades: Stryker, Editas Medicine, Oracle & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols:ORCLSYK
1 week ago - CNBC Television

3 Red-Hot Healthcare Stocks to Buy in September

These businesses are firing on all cylinders.

Other symbols:DHRVEEV
2 weeks ago - The Motley Fool

Initial Clinical Data from Editas Medicine's BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the I...

Data to include patient safety assessments and a preliminary analysis of secondary endpoints to evaluate biological activity

2 weeks ago - GlobeNewsWire

Why Is Editas (EDIT) Up 33.8% Since Last Earnings Report?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

2 weeks ago - Zacks Investment Research

Forget About the Genomic Revolution, the Proteomic Revolution Is Coming

Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. The post Forget About the Genomic Rev...

Other symbols:BEAMILMNNTLA
3 weeks ago - InvestorPlace

Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today

Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology. The post Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and ...

Other symbols:CRSPNTLA
1 month ago - InvestorPlace

Editas Medicine Unveils Preclinical Data From New Gene Editing Technology

Editas Medicine Inc (NASDAQ: EDIT) announced data on a new gene-editing technology termed SLEEK (SeLection by Essential-gene Exon Knock-in).  Data were presented at the Cold Spring Harbor Laboratory's G...

1 month ago - Benzinga

Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratory's Genome Engineer...

SLEEK enables high efficiency, multi-transgene knock-in of induced Pluripotent Stem Cells (iPSCs), T cells, and Natural Killer (NK) cells

1 month ago - GlobeNewsWire

Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why

Editas' (EDIT) lead candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating hematologic diseases.

1 month ago - Zacks Investment Research

Will Moderna's Interest Boost Gene Editing Stocks?

Our indicative theme of Gene Editing stocks has returned about 11% year-to-date, compared to the S&P 500 which is up by about 19% over the same period. However, the gains have overwhelmingly come from a...

Other symbols:NTLASGMO
1 month ago - Forbes

How Are Genomics ETFs Responding to Q2 Earnings?

Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.

1 month ago - Zacks Investment Research

Will Moderna Buy Editas Medicine to Jump Into Gene Editing?

Editas could be an attractive acquisition candidate for the big vaccine maker.

Other symbols:MRNA
1 month ago - The Motley Fool

Will The Rally In Editas Stock Continue After A 20% Rise In A Month?

The stock price of Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has seen a rise of over 20% over the last twenty-one trading days, and it is a...

1 month ago - Forbes

Why Editas Medicine Beat the Market on Monday

Another analyst ups his recommendation on the stock.

1 month ago - The Motley Fool

Monday Afternoon Analyst Upgrades and Downgrades: Caesars, Coinbase, Editas, Wynn and More

With the trading day more than halfway over, the broad markets were fairly mixed. While the Dow Jones industrial average and S&P 500 had pulled back slightly from their all-time highs, they still seem p...

1 month ago - 24/7 Wall Street

Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today

Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. The post Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are C...

Other symbols:CRSPNTLA
1 month ago - InvestorPlace

Editas (EDIT) Q2 Earnings Beat Estimates, Revenues Fall Y/Y

Editas (EDIT) reports narrower-than-expected loss in the second quarter of 2021 while revenues miss estimates. Focus remains on the development of CRISPR gene-editing candidate, EDIT-101.

1 month ago - Zacks Investment Research

Thursday Afternoon Analyst Upgrades and Downgrades: Bath & Body Works, Editas, GoDaddy, PetMed, Qorvo and More

With the trading day about halfway over, S&P 500, Nasdaq and Dow Jones industrial average were pushing higher for a number of reasons.

1 month ago - 24/7 Wall Street

Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of 4.71% and -94.33%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Editas Medicine Announces Second Quarter 2021 Results and Business Updates

Enrolling first pediatric and adult high dose cohorts of EDIT-101 BRILLIANCE trial for LCA10

1 month ago - GlobeNewsWire

Editas (EDIT) to Report Q2 Earnings: What's in the Cards?

On Editas' (EDIT) second-quarter earnings call, investor focus will likely be on the company's progress with the development of EDIT-101, its lead pipeline candidate.

1 month ago - Zacks Investment Research

Editas Medicine (EDIT) Stock Moves -0.1%: What You Should Know

In the latest trading session, Editas Medicine (EDIT) closed at $41.86, marking a -0.1% move from the previous day.

1 month ago - Zacks Investment Research